TScan Therapeutics Director Departs, Becomes Senior Advisor
Ticker: TCRX · Form: 8-K · Filed: Apr 2, 2026 · CIK: 0001783328
| Field | Detail |
|---|---|
| Company | Tscan Therapeutics, Inc. (TCRX) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, consulting-agreement
Related Tickers: TCRX
TL;DR
TScan director Altschuler out, but in as CEO advisor. Consulting deal signed.
AI Summary
TScan Therapeutics, Inc. announced on March 31, 2026, the departure of Dr. Steven D. Altschuler from its Board of Directors. The company also appointed Dr. Altschuler as a Senior Advisor to the CEO, effective April 1, 2026, and entered into a consulting agreement with him.
Why It Matters
The departure of a director and subsequent appointment as a senior advisor can signal strategic shifts or a desire for specialized expertise in a company's leadership.
Risk Assessment
Risk Level: low — This filing primarily concerns a change in board composition and a consulting agreement, which typically carries low immediate risk.
Key Players & Entities
- TScan Therapeutics, Inc. (company) — The company filing the report.
- Dr. Steven D. Altschuler (person) — Departing director and newly appointed Senior Advisor.
- March 31, 2026 (date) — Effective date of departure.
- April 1, 2026 (date) — Effective date of Senior Advisor role.
FAQ
What was the effective date of Dr. Altschuler's departure from the Board of Directors?
Dr. Steven D. Altschuler's departure from the Board of Directors was effective March 31, 2026.
What new role has Dr. Altschuler taken on at TScan Therapeutics?
Dr. Altschuler has been appointed as a Senior Advisor to the CEO.
When did Dr. Altschuler's role as Senior Advisor become effective?
His role as Senior Advisor to the CEO became effective on April 1, 2026.
Has TScan Therapeutics entered into any agreements with Dr. Altschuler?
Yes, TScan Therapeutics has entered into a consulting agreement with Dr. Altschuler.
What is the CIK number for TScan Therapeutics, Inc.?
The CIK number for TScan Therapeutics, Inc. is 0001783328.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2026-04-02 07:30:07
Key Financial Figures
- $0.0001 — istered Voting Common Stock, par value $0.0001 per share TCRX The Nasdaq Global Ma
Filing Documents
- d923169d8k.htm (8-K) — 24KB
- 0001193125-26-138973.txt ( ) — 135KB
- tcrx-20260331.xsd (EX-101.SCH) — 3KB
- tcrx-20260331_lab.xml (EX-101.LAB) — 18KB
- tcrx-20260331_pre.xml (EX-101.PRE) — 11KB
- d923169d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TScan Therapeutics, Inc. Date: April 2, 2026 By: /s/ Gavin MacBeath Gavin MacBeath Chief Executive Officer